Skip to main content

High jumper Ivan Ukhov competes at the Russian national winter athletics meet in Moscow on Feb. 5, 2017.

Ivan Sekretarev/The Associated Press

Some of Russia’s best known track and field athletes are facing doping cases, including former Olympic high jump champion Ivan Ukhov.

The Athletics Integrity Unit, which oversees anti-doping cases in track and field, released details on Friday of 109 cases from around the world in a new transparency drive.

Besides Ukhov, the list includes top Russians such as the double world champion shot putter Tatyana Lysenko, Olympic bronze medal-winning long jumper Svetlana Shkolina, and 2014 world indoor triple jump champion Lyukman Adams.

Story continues below advertisement

The AIU said they are among 13 Russian cases based on evidence uncovered during World Anti-Doping Agency investigator Richard McLaren’s research into a widespread system of doping and coverups in Russia.

The cases of Ukhov, Lysenko, Adams, and Shkolina are all listed as pending before the Court of Arbitration for Sport.

Some of the 13 have competed in recent months, and the AIU said they weren’t suspended ahead of a hearing.

“Where there is a case that doesn’t involve a positive test but is the result of an investigation based on McLaren evidence only, the athlete can continue to compete until their case is determined,” the AIU said in emailed comments to The Associated Press.

There’s also a case against two-time world championship medallist Anisya Kirdyapkina based on suspicious blood values in samples she gave to drug testers.

Kirdyapkina was on Russia’s national race-walking team during a time when doping was widespread, leading to bans for more than 30 athletes, including her husband Sergei Kirdyapkin, and a life ban for the head coach Viktor Chegin.

Among athletes from outside Russia, the AIU release also revealed reigning Olympic women’s marathon champion, Kenyan runner Jemima Sumgong, faces another doping hearing on allegations of “tampering” with a drug test. Sumgong is already banned until 2021 after testing positive for the banned drug EPO last year.

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter